These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

692 related items for PubMed ID: 20050849

  • 1. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.
    Schafer PH, Parton A, Gandhi AK, Capone L, Adams M, Wu L, Bartlett JB, Loveland MA, Gilhar A, Cheung YF, Baillie GS, Houslay MD, Man HW, Muller GW, Stirling DI.
    Br J Pharmacol; 2010 Feb; 159(4):842-55. PubMed ID: 20050849
    [Abstract] [Full Text] [Related]

  • 2. Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex.
    Schafer PH, Truzzi F, Parton A, Wu L, Kosek J, Zhang LH, Horan G, Saltari A, Quadri M, Lotti R, Marconi A, Pincelli C.
    Cell Signal; 2016 Jul; 28(7):753-63. PubMed ID: 26806620
    [Abstract] [Full Text] [Related]

  • 3. Apremilast Normalizes Gene Expression of Inflammatory Mediators in Human Keratinocytes and Reduces Antigen-Induced Atopic Dermatitis in Mice.
    Schafer PH, Adams M, Horan G, Truzzi F, Marconi A, Pincelli C.
    Drugs R D; 2019 Dec; 19(4):329-338. PubMed ID: 31598889
    [Abstract] [Full Text] [Related]

  • 4. The phosphodiesterase 4 inhibitor apremilast inhibits Th1 but promotes Th17 responses induced by 6-sulfo LacNAc (slan) dendritic cells.
    Oehrl S, Prakash H, Ebling A, Trenkler N, Wölbing P, Kunze A, Döbel T, Schmitz M, Enk A, Schäkel K.
    J Dermatol Sci; 2017 Aug; 87(2):110-115. PubMed ID: 28499587
    [Abstract] [Full Text] [Related]

  • 5. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast.
    Gottlieb AB, Strober B, Krueger JG, Rohane P, Zeldis JB, Hu CC, Kipnis C.
    Curr Med Res Opin; 2008 May; 24(5):1529-38. PubMed ID: 18419879
    [Abstract] [Full Text] [Related]

  • 6. Phosphodiesterase-4 Inhibition Reduces Cutaneous Inflammation and IL-1β Expression in a Psoriasiform Mouse Model but Does Not Inhibit Inflammasome Activation.
    Meier-Schiesser B, Mellett M, Ramirez-Fort MK, Maul JT, Klug A, Winkelbeiner N, Fenini G, Schafer P, Contassot E, French LE.
    Int J Mol Sci; 2021 Nov 28; 22(23):. PubMed ID: 34884681
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Astragaloside IV suppresses the proliferation and inflammatory response of human epidermal keratinocytes and ameliorates imiquimod-induced psoriasis-like skin damage in mice.
    Liu T, Ai L, Jiang A, Wang Y, Jiang R, Liu L.
    Allergol Immunopathol (Madr); 2024 Nov 28; 52(5):44-50. PubMed ID: 39278850
    [Abstract] [Full Text] [Related]

  • 9. Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis.
    Pincelli C, Schafer PH, French LE, Augustin M, Krueger JG.
    J Drugs Dermatol; 2018 Aug 01; 17(8):835-840. PubMed ID: 30124722
    [Abstract] [Full Text] [Related]

  • 10. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.
    Schafer PH, Parton A, Capone L, Cedzik D, Brady H, Evans JF, Man HW, Muller GW, Stirling DI, Chopra R.
    Cell Signal; 2014 Sep 01; 26(9):2016-29. PubMed ID: 24882690
    [Abstract] [Full Text] [Related]

  • 11. Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis.
    Bianchi L, Del Duca E, Romanelli M, Saraceno R, Chimenti S, Chiricozzi A.
    Expert Opin Drug Metab Toxicol; 2016 Sep 01; 12(9):1121-8. PubMed ID: 27376729
    [Abstract] [Full Text] [Related]

  • 12. Proinflammatory cytokine production in HaCaT cells treated by eosin: implications for the topical treatment of psoriasis.
    Zampetti A, Mastrofrancesco A, Flori E, Maresca V, Picardo M, Amerio P, Feliciani C.
    Int J Immunopathol Pharmacol; 2009 Sep 01; 22(4):1067-75. PubMed ID: 20074471
    [Abstract] [Full Text] [Related]

  • 13. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.
    Schafer P.
    Biochem Pharmacol; 2012 Jun 15; 83(12):1583-90. PubMed ID: 22257911
    [Abstract] [Full Text] [Related]

  • 14. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.
    Gottlieb AB, Matheson RT, Menter A, Leonardi CL, Day RM, Hu C, Schafer PH, Krueger JG.
    J Drugs Dermatol; 2013 Aug 15; 12(8):888-97. PubMed ID: 23986162
    [Abstract] [Full Text] [Related]

  • 15. Facile skin targeting of a thalidomide analog containing benzyl chloride moiety alleviates experimental psoriasis via the suppression of MAPK/NF-κB/AP-1 phosphorylation in keratinocytes.
    Tang KW, Lin ZC, Wang PW, Alalaiwe A, Tseng CH, Fang JY.
    J Dermatol Sci; 2020 Aug 15; 99(2):90-99. PubMed ID: 32622642
    [Abstract] [Full Text] [Related]

  • 16. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
    Ohtsuki M, Okubo Y, Komine M, Imafuku S, Day RM, Chen P, Petric R, Maroli A, Nemoto O.
    J Dermatol; 2017 Aug 15; 44(8):873-884. PubMed ID: 28391657
    [Abstract] [Full Text] [Related]

  • 17. Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors.
    Perez-Aso M, Montesinos MC, Mediero A, Wilder T, Schafer PH, Cronstein B.
    Arthritis Res Ther; 2015 Sep 15; 17(1):249. PubMed ID: 26370839
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Protectin D1 reduces imiquimod-induced psoriasiform skin inflammation.
    Park KD, Kim N, Kang J, Dhakal H, Kim JY, Jang YH, Lee WJ, Lee SJ, Kim SH.
    Int Immunopharmacol; 2021 Sep 15; 98():107883. PubMed ID: 34153674
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.